Amarin (AMRN) Produces Drugs Faster than It Can Get Patents
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Join SI Premium – FREE
Amarin (Nasdaq: AMRN) is quick. Almost too quick.
Shares are trading flat late Thursday as the WSJ reports its development of a experimental heart drug derived from fish oil was so fast, that it may be ready to market before the last key block is in place: patent approval.
Despite arguably the best MacGyvering done to produce a lifesaving drug by a biotech firm to-date, Amarin's patents for AMR101 hit a snag earlier in the week when the U.S. Patent and Trademark Office (USPTO) posted additional non-final rejections.
Though the drug is expected to get FDA approval in late-July, no patents means Amarin could lose billions, according to analysts cited by the WSJ.
Amarin ended about 1.5 percent lower Thursday following the report. Shares were up as much as 6.4 percent at one point.
Shares are trading flat late Thursday as the WSJ reports its development of a experimental heart drug derived from fish oil was so fast, that it may be ready to market before the last key block is in place: patent approval.
Despite arguably the best MacGyvering done to produce a lifesaving drug by a biotech firm to-date, Amarin's patents for AMR101 hit a snag earlier in the week when the U.S. Patent and Trademark Office (USPTO) posted additional non-final rejections.
Though the drug is expected to get FDA approval in late-July, no patents means Amarin could lose billions, according to analysts cited by the WSJ.
Amarin ended about 1.5 percent lower Thursday following the report. Shares were up as much as 6.4 percent at one point.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amarin Corp. (AMRN) Reports In-Line Q2 EPS
- Aprea expands cancer trial sites and plans Q4 2026 data update
- FDA approves Novartis Pluvicto for earlier-stage prostate cancer
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
